Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France

作者：Benjamin Wyplosz, Benjamin Grenier, Nicolás Roche, François Roubille, Paul Loubet, Ariane Sultan, Bertrand Fougère, Jérôme Fernandes, Didier Duhot, Bruno Moulin, F. Raguideau, E. Blanc, G. Goussiaume · 发表于：PLoS ONE · 年份：2025 · DOI：10.1371/journal.pone.0329703 · 被引用次数：5 · 研究领域：Pneumonia and Respiratory Infections、Influenza Virus Research Studies、Respiratory viral infections research

OBJECTIVES: Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years). METHODS: We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021. RESULTS: In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age ≥65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, in...